- Home
- ESLA vs BYSI Comparison
ESLA vs BYSI Comparison
Compare ESLA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.06
HOLD
Current Price
$1.67
Company Overview
Basic Information| Metric | ESLA | BYSI |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9M | 67.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ESLA | BYSI |
|---|---|---|
| Price | $1.06 | $1.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 45.7K | 22.3K |
| Earning Date | 03-18-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.98 |
| 52 Week High | $3.15 | $3.44 |
Technical Indicators
Market Signals| Indicator | ESLA | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 59.12 |
| Support Level | $1.01 | $1.70 |
| Resistance Level | $1.35 | $1.83 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 14.04 | 64.86 |
Price Performance
Historical Comparison ESLA
BYSI
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.